Friday, 22 Jun 2018

You are here

Cardiovascular Risk Factors in Psoriasis, PsA and Seronegative SpA

Not a surprise to anyone anymore, increased risk of cardiovascular disease poses a danger of significant morbidity and mortality in patients underlying inflammatory arthritides. A single center cross -sectional observational study was designed to conduct deeper analysis of Cardiovascular Risk Factors (CVRF) in patients with PsA, PSO without arthritis and SpA without PSO (THU 0297). Authors aimed at identifying association between CVRF and presence of either arthritis or skin disease. 

In this study of 300 patients with PSA, PSO and SpA, 29.7% reported Hypertension (HTN), 11.7% Type 2 Diabetes Melitus(T2DM) and 29% Dyslipidemia (DL). In comparison with general population entire study group comprised 100 patients with SpA without PSO (33.3%), 100 patients with PsA (33.3%) and PSO without articular disease (13%) exhibited higher prevalence of HTN and DL (p <0.005). Inside the study group though, where was no significant difference in prevalence of CVEF between all three studied diagnoses ( Fig below).

HTN was significantly associated with AINEs intake (OR 1.79; p<0.005) and disease duration (OR 1.02). No association with gender or age was found in this study.  neither PSA/SpA nor PSO were associated with development of T2DM or dyslipidemia. 

Study concluded that although prevalence of CVRF was higher in the study group comparing to general population, no significant difference was found in regards to skin vs articular disease. authors hint at association between NSAIDs use and HTN which would require further studies to specify.

image2.jpeg

 

image3.jpeg

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Cosentyx Gets Radiographic Protection Indication for Psoriatic Arthritis

Novartis announced today that the US Food and Drug Administration (FDA) approved the inclusion of new evidence that Cosentyx® (secukinumab) significantly slows the progression of joint structural damage at Week 24 versus placebo in those with active psoriatic arthritis (PsA).

Increased Risk of Infection in Psoriasis and Psoriatic Arthritis

As we gather more knowledge about psoriatic arthritis ( PsA) and psoriasis (PSO) over time, and achieve better outcomes with new therapies, more questions arise about quality of life, survival  and comorbidities in PsA and PSO. Similarly to RA, we learned about increased risk of CVD and malignancy. With more data compiled in cohorts it is possible now to ask the same questions as we asked in RA.

MRI Imaging for Sacroiliitis Requires Bone Marrow Edema for Reliability

de Winter and colleagues from the Netherlands have reported on magnetic resonance imaging of the sacroiliac joints of healthy subjects, patients with axial spondyloarthritis, runners and those with chronic back pain, and found a high incidence of sacroiliitis in many, but that deep bone marrow edema was most specific for those with axial SpA.

Cancer Risk Raised in Psoriatic Arthritis

Patients with psoriatic arthritis (PsA) were at increased risks for malignancy, and possibly more so if they were treated with conventional disease-modifying antirheumatic drugs (DMARDs), a meta-analysis found.

In nine cohort studies that included more than 43,000 PsA patients, the pooled relative risk for overall malignancy was 1.29 (95% CI 1.04-1.60) compared with the general population, according to Yunyun Fei, MD, and colleagues from Peking Union Medical College in Beijing.

Trends in Psoriatic Arthritis Treatment 2004-2015

Lee and colleagues from Brigham and Women's Hospital have analyzed the last decade of disease‐modifying antirheumatic drugs (DMARDs) use in patients with psoriatic arthritis (PsA) and found nearly 40% were treated with a bDMARD, along with a decreasing trend in complete DMARD discontinuations.